SLC5A2 and diabetes mellitus: Guidelines also suggest sodium/glucose cotransporter-2 (SGLT2) inhibitors should be prescribed to decrease the risk of diabetic kidney disease progression in type 2 diabetes mellitus patients [9, 11, 12].